Hereditary and acquired antithrombin deficiency

Seminars in Thrombosis and Hemostasis

Volumn 25, Issue 3, 1999, Pages 257-263

  Vinazzer, Helmut ^a  

^a Laboratory for Blood Coagulation   (Austria)

Author keywords

Antithrombin (AT); AT concentrates; AT deficiency; DIC; Heparin; Sepsis

Indexed keywords

ANTITHROMBIN;

ANTITHROMBIN DEFICIENCY; CONFERENCE PAPER; DISEASE ASSOCIATION; DISSEMINATED INTRAVASCULAR CLOTTING; GENE MUTATION; HUMAN; NUCLEIC ACID BASE SUBSTITUTION; PATHOGENESIS; PRIORITY JOURNAL; SEPSIS; THROMBOSIS;

EID: 0032803269     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-994929     Document Type: Conference Paper

References (74)

1. Morawitz P. Die chemie der blutgerinnung. Ergebn Physiol 1905;4:307
2. Seegers WH. Multiple protein interactions as exhibited by the blood clotting mechanism. J Phys Colloid Chem 1947;51:198
3. Astrup T, Darling S. Measurement and properties of antithrombin. Acta Physiol Scand 1942;4:293
4. Seegers WH. A new plasma antithrombin reaction. Arch Biochem Biophys 1952;36:484
5. Seegers WH, Johnson WF, Fell C. An antithrombin reaction related to prothrombin activation. Am J Physiol 1954;176:97
6. Loeliger EA, Ilers JFPh. Chronic antithrombinemia (Antithrombin V) with hemorrhagic diathesis in a case of rheumatoid arthritis in a case of hypergammglobulinaemia. Thromb Diath Haemorrhag 1957;1:499
7. Vinazzer H, Reinhardt F. On the nature of antithrombin V. Thromb Diath Haemorrhag 1968;20:233
8. Niewiarowski S, Kowaralski E. Un nouvel anticoagulant dérivé du fibrinogène. Rev Hématol 1958;13:320
9. Petersen TE, Dudek-Wojiciechowska G, Sottrup-Jensen L, Magnusson S. Primary structure of antithrombin III (heparin cofactor). Partial homology between alpha-I-antitrypsin and antithrombin III. In: Collen D, Wiman B, Verstraete M, eds. The Physiological Inhibitors of Coagulation and Fibrinolysis. Amsterdam: Elsevier; 1979:43
10. Blaskó G. The active site of AT III. In: Sas G, ed. The Biology of Antithrombins. Boca Raton, FL: CRC Press, 1990:5
11. Léon M, Aiach M, Coezy E, Guennec JY, Fiessinger JN. Antithrombin III synthesis in rat liver parenchymal cells. Thromb Res 1985;30:369
12. Nakagawa M, Kitany T, Watada M, et al. Biosynthesis and metabolism of antithrombin III. Acta Haematol (Japan) 1981;44:1479
13. Griffith MJ, Lundblad RL, Dissociation of AT III-thrombin complex. Formation of active and inactive AT III. Biochemistry 1981;20:105
14. Vinazzer H, Blauhut B, Bergmann H. Die antithrombin III substitution bei patienten im schock. Folia Haematol (Leipzig) 1984;3:806
15. Hensen A, Loeliger EA. Antithrombin III assay. In: Hensen A, Loeliger EA, eds. Antithrombin III. Stuttgart: Schattauer, 1963:18
16. Abildgaard U. Inhibition of the thrombin-fibrinogen reaction by heparin and purified co-factor. Scand J Haematol 1968;5:440
17. Heimburger N. On the proteinase inhibitors of human plasma with special reference to antithrombin. In: First International Symposium: Tissue Factors in the Haemostasis of the Coagulation-Fibrinolysis System. Florence, 1967
18. Egeberg O. Inherited antithrombin III deficiency causing thrombophilia. Thromb Diath Haemorrhag 1965;13:516
19. Hakten M, Deniz U, Özbay G, Ulutin ON. Two cases of homozygous antithrombin III deficiency in a family with congenital deficiency of AT III. In: Sinzinger H, Vinazzer H, eds. Thrombosis and Haemorrhagic Disorders. Würzburg: Schmitt & Meyer; 1989:177
20. Sas G, Blaskó G, Banhegyi D, Jákó J, Pálos I.A. Abnormal antithrombin III (Antithrombin III Budapest) as a cause of a familial thrombophilia. Thromb Diath Haemorrhag 1974;32:105
21. Tengborn I., Frohm B, Nisson L-E, Nilsson IM. A Swedish family with abnormal antithrombin III. Scand J Haematol 1985;34:412
22. Murayama H, Matsuda M. Abnormal antithrombin III with defective biological and immunological functions found in a thrombophilic patient - Antithrombin III Tokyo. Thromb Haemost 1983;50:358
23. Bauer KA, Ashenhurst JB, Chediak J, Rosenberg RD. Antithrombin III "Chicago" a Functionally Abnormal Molecule with Increased Heparin Affinity Causing Familial Thrombophilia.
24. Girolami A, Marafiotti F, Rubertelli M, et al. Antithrombin III Trento. A new congenital AT III abnormality with a peculiar crossed-immunoelectrophoretic pattern in the absence of heparin. Acta Haematol 1984;72:73
25. Brozovic M, Stirling Y, Hamlyn AN. Thrombotic tendency and probable antithrombin III deficiency. Thromb Haemost 1978;39:778
26. Wolf M, Boyer C, Tripodi A, et al. Antithrombin Milano, a new variant with monomeric and dimeric inactive antithrombin III. Blood 1985;65:496
27. Lane DA, Lowe GDD, Flynn A, et al. Antithrombin III Glasgow, a variant with increased heparin affinity and reduced ability to inactivate thrombin associated with familial thrombosis. Thromb Haemost 1987;58:427
28. Sörensen PJ, Dyerberg J, Stoffersen E, Krog-Jensen M. Familial functional antithrombin III deficiency. Scand J Haematol 1980;24:105
29. Barbui T, Rodeghiero F. Hereditary dysfunctional antithrombin III (AT III Vicenza). Thromb Haemost 1981;45:97
30. Jörgensen M, Petersen LC. Purification and characterization of hereditary abnormal antithrombin III with impaired thrombin binding. J Lab Clin Med 1984;104:245
31. Sambrano JE, Jacobson LJ, Reeve EB, Manco-Johnson MJ, Hathaway WE. Abnormal antithrombin III with defective serine protease binding (Antithrombin III Denver). J Clin Invest 1986;77:887
32. Aiach M, Nora M, Fiessinger JN, et al. A functional abnormal antithrombin III deficiency (AT III Charleville). Thromb Res 1985;39:559
33. Tripodi A, Krachmalnikoff A, Mannucci PM. Characterization of an abnormal antithrombin (Milano 2) with defective thrombin binding. Thromb Haemost 1986;56:349
34. Leone G, De Stefano V, Di Donfrancesco A, et al. Antithrombin III Pescara: A defective AT III variant with no alterations of plasma crossed immunoelectrophoresis but with an abnormal crossed immunoelectrofocusing pattern. Br J Haematol 1987;65:187
35. Carter CJ, Johnson M, Brain MC, Glynn MFX. A new antithrombin III variant presenting as familial thrombophilia. Blood 1981;58:231a (Abst)
36. Aiach M, Roncato M, Sorin G, Dezullus P, Fiessinger JN. A new AT III variant with detective protease binding site. Thromb Haemost 1987;58:38
37. Tran TH, Bounameaux H, Bondeli C, et al. Purification and partial characterization of a hereditary abnormal antithrombin III fraction of a patient with recurrent thrombophlebitis. Thromb Haemost 1980;44:87
38. Wolf M, Boyer C, Lavergne JM, Larrieux MJ. A new familial variant of antithrombin III: "Antithrombin III Paris." Br J Haematol 1982;51:285
39. Girolami A, Pengo V, Cappellato G, et al. Antithrombin III Padua, a new congenital abnormality with normal or near normal activity, normal antigen, abnormal migration and no thrombotic disease. Folia Haematol (Leipzig) 1983;110:98
40. Girolami A, Fabris F, Cappellato G, Sainati L, Boeri G. Antithrombin III Padua, a new congenital abnormality with defective heparin co-factor activities but not thrombotic disease. Blut 1983;47:93
41. Sakuragawa N, Takahashi K, Kondo S, Koide T. Antithrombin III Toyama, a hereditary abnormal antithrombin III of a patient with recurrent thrombophlebitis. Thromb Res 1983;31:305
42. Fischer AM, Gazengel C, Dautzenberg MD, et al. A new case of abnormal antithrombin III. Biological characteristics and thromboembolic accidents management. Thromb Haemost 1983;50:358
43. Chasse JF, Esnard F, Guitton JD, et al. An abnormal plasma antithrombin with no apparent affinity for heparin. Thromb Res 1984;34:297
44. Fischer AM, Cornu P, Sternberg C, et al. Antithrombin III Alger: A new homozygous AT III variant. Thromb Haemost 1986;55:218
45. Boyer C, Wolf M, Vedrenne J, Meyer D, Larrieu MJ. Homozygous variant of antithrombin III: AT III Fontainebleau. Thromb Haemost 1986;56:18
46. de Moerloose PA, Reber G, Vernet Ph, Minazio Ph, Bouvier CA. Antithrombin III Geneva: A hereditary abnormal AT III with defective heparin cofactor activity. Thromb Haemost 1987;57:154
47. Owen MC, Borg VY, Soria C, et al. Heparin binding reduction in a new antithrombin III variant Rouen 47 Arg to His. Blood 1987;69:1275
48. Borg JY, Owen MC, Soria C, et al. Antithrombin Rouen I (47 Arg-His) and Rouen III (47 Ser), two new variants with decreased heparin affinity. Thromb Haemost 1987;58:238
49. Roussel B, Dieval J, Gross S, Claisse JF, Delobel J. A new asymptomatic type III variant of antithrombin III with decreased heparin cofactor activity: AT III Amiens. Thromb Haemost 1987;58:427
50. Aiach M, Francois D, Priollet P, et al. An abnormal antithrombin III with low heparin affinity: AT III Clichy. Br J Haematol 1987;66:515
51. Cosgriff TM, Bishop DT, Hershgold EJ, et al. Familial antithrombin III deficiency: Its natural history, genetics, diagnosis and treatment. Medicine 1983;62:209
52. Bock SC, Harris JF, Schwartz CE, et al. Hereditary thrombosis in a Utah kindred is caused by a dysfunctional antithrombin III gene. Am J Hum Genet 1985;37:32
53. Matsuo T, Ohky Y, Kondo S, Matsuo O. Familial antithrombin III deficiency in a Japanese family. Thromb Res 1979;16:815
54. Penner JA, Hassouna H, Hunter MJ, Chockley MA. A clinically silent antithrombin III defect in an Ann Arbor family. Thromb Haemost 1979;42:186
55. Kolde T, Takahashi K, Odani S, Ono T, Sakuragawa N. Isolation and characterization of a hereditary abnormal antithrombin III: "Antithrombin III Toyama." Thromb Res 1983;31:319
56. Kolde T, Odani S, Takahashi K, Ono T, Sakuragawa N. Antithrombin III Toyama replacement of Arg 47 by cysteine in hereditary abnormal antithrombin III that lacks heparin binding ability. Proc Natl Acad Sci USA 1984;81:289
57. Thaler E, Balzär E, Kopsa H, Pinggera EF. Acquired antithrombin III deficiency in patients with glomerular proteinuria. Haemostasis 1978;7:257
58. Vinazzer H. Antithrombin III in shock and disseminated intravascular coagulation. Clin Appl Thromb Hemost 1995;1:62
59. Thaler E, Lechner K. Antithrombin III deficiency and thromboembolism. Clin Haematol 1981;10:369
60. Vinazzer H. Clinical use of antithrombin III concentrates. Vox Sang 1987;53:193
61. Blauhut B, Necek S, Kramar H, Vinazzer H, Bergmann H. Activity of antithrombin III and effect of heparin on coagulation in shock. Thromb Res 1980;19:775
62. Büller HR, ten Cate JW. Antithrombin III infusion in patients undergoing peritoneal venous shunt operation: Failure in the prevention of disseminated intravascular coagulation. Thromb Haemost 1983;49:128
63. Korninger C, Klepetko W, Miholic J, Schwarz Ch, Lechner K. Randomized trial of antithrombin III versus placebo in patients undergoing peritoneal venous shunt operation. Thromb Haemost 1987;58:426
64. Kaufmann RH, Veltkamp JJ, Tilburg NH, van Es LA. Acquired antithrombin III deficiency and thrombosis in the nephrotic syndrome. Am J Med 1978;65:607
65. Blauhut B, Necek S, Vinazzer H, Bergmann H. Substitution therapy with an antithrombin III concentrate in shock and DIC. Thromb Res 1982;27:271
66. Blauhut B, Kramar H, Vinazzer H, Bergmann H. Substitution of antithrombin III in shock and DIC: A randomized study. Thromb Res 1985;39:81
67. Hellgren M, Javelin L, Hägnevik K, Blombäck M, Meden-Britth G. Antithrombin III concentrate an adjuvant in DIC treatment: A pilot study in nine severely ill patients. Thromb Res 1985;35;459
68. Kreuz WD. Antithrombin III substitution therapy in children with acquired AT III deficiency. In: Breddin HK, Bender N, Scharf RE, eds. Recent Advances and New Developments in Hemostaseology. Basel: Karger, 1986:105
69. Spero JA, Lewis JH, Hasiba U. Disseminated intravascular coagulation: Findings in 346 patients. Thromb Haemost 1980;43:28
70. Aasen AO, Smith-Erichsen N, Amundsen E. Studies on pathological plasma proteolysis in patients with septicemia. Scand J Clin Lab Invest 1985;Suppl 178:37
71. Seitz R, Wolf M, Egbring R. Antithrombin III and plasma substitution in septic shock. Prog Clin Biol Res 1989;308:965
72. Seitz R, Wolf M, Egbring R, Havemann K. The disturbance of hemostasis in septic shock. Role of neutrophil elastase and thrombin: Effects of antithrombin III and plasma substitution. Eur J Haematol 1989;43:22
73. Fourrier F, Chopin C, Huart JJ, et al. Double blind placebo-controlled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation. Chest 1993;104:882
74. Dickneite G, Paques EP. Reduction of mortality with antithrombin III in septicemic rats: A study of Klebsiella pneumoniae induced sepsis. Thromb Haemost 1993;69:98